Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
D0I3GT
|
|||
| Former ID |
DIB001883
|
|||
| Drug Name |
Live attenuated recombinant vaccine
|
|||
| Synonyms |
Live attenuated recombinant vaccine (chikungunya virus infection); Chikungunya virus vaccine (live attenuated recombinant), InViragen; Live attenuated recombinant vaccine (chikungunya virus infection), InViragen; Vaccine (chikungunya virus infection), InViragen; Vaccine (chikungunya virus infection), University of Texas Medical Branch
Click to Show/Hide
|
|||
| Indication | Chikungunya virus infection [ICD-11: 1D40; ICD-9: 001-139, 042-075] | Phase 2 | [1] | |
| Company |
Inviragen
|
|||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT01511250) Study to Investigate the Safety and Immunogenicity of a Tetravalent Chimeric Dengue Vaccine in Healthy Volunteers Between the Ages of 1.5 - 45 Years. U.S. National Institutes of Health. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.